Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00757874|
Recruitment Status : Completed
First Posted : September 23, 2008
Last Update Posted : September 9, 2015
Lichen Sclerosus is an inflammatory skin condition affecting mostly the genital area of persons of all ages, gender or race. The most frequent complaint is that of itchiness of the vulva but pain may also occur. Some women will experience no symptoms at all. However, it is important to treat this condition since it may increase and cause important scarring and deformity. In less than 5% of cases, cancer may develop.
Lichen Sclerosus is a chronic disease which can be controlled but not cured. Topical corticosteroids are the usual treatment for this condition. Though this treatment is generally well tolerated, some patients may not present a sufficient response or may develop mainly local and rarely systemic side effects. In this perspective, an alternative treatment would be beneficial.
Tacrolimus, a topical immunomodulator has been approved for the treatment of atopic eczema and has shown its efficacy in the treatment of vulvar lichen sclerosus in a limited number of patients. Tacrolimus acts as a non-steroidal anti-inflammatory agent (NSAI) without causing the usual side effects seen with the prolonged use of topical corticosteroids.
This study is designed to evaluate the safety and efficacy of tacrolimus in treating vulvar lichen sclerosus by comparing it with the standard topical corticosteroid treatment.
|Condition or disease||Intervention/treatment||Phase|
|Vulvar Lichen Sclerosus||Drug: Tacrolimus cream Drug: Clobetasol cream||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus.|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||January 2010|
|Experimental: Tacrolimus cream||
Drug: Tacrolimus cream
0.5 g per day at bed time for 3 months or less.
Other Name: Prtopic
|Active Comparator: Clobetasol cream||
Drug: Clobetasol cream
0.5 gram each day at bed time during 3 months or less.
Other Name: Dermovate
- To document the efficacy of Tacrolimus vs topical clobetasol propionate in the treatment of Vulvar Lichen Sclerosus by medical examinations and reporting of the symptoms. Cream is applied once a day for 3 months [ Time Frame: Comparison before the treatment and monthly for 3 months. ]
- Compared presence and severity of side effects of both groups. [ Time Frame: During the 3 months of treatment ]
- CBC, Glycemia, vitamine B 12 dosage, TSH (to find associated auto-immune diseases) [ Time Frame: At 1 to 3 months after starting the study, collected once. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757874
|Montreal, Quebec, Canada, H3P 3N5|
|Principal Investigator:||Deana Funaro, Doctor||St. Justine's Hospital|